InvestorsHub Logo
Post# of 252488
Next 10
Followers 31
Posts 3757
Boards Moderated 0
Alias Born 01/29/2012

Re: None

Monday, 11/26/2018 4:50:51 PM

Monday, November 26, 2018 4:50:51 PM

Post# of 252488
BMY Announces CheckMate -451 Study Did Not Meet Primary Endpoint of Overall Survival with Opdivo Plus Yervoy Vs. Placebo as A Maintenance Therapy in Patients with Extensive-Stage Small Cell Lung Cancer After Completion of First-Line Chemotherapy
https://news.bms.com/press-release/corporatefinancial-news/bristol-myers-squibb-announces-checkmate-451-study-did-not-mee

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.